Could vitamin d help fight blood cancer?
NCT ID NCT02553447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving vitamin D supplements to people with low vitamin D levels and newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia could improve their outcomes. About 197 participants received either a low or high dose of vitamin D while undergoing standard cancer care. The goal was to see if raising vitamin D levels could help delay cancer progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
197 people
The number who actually took part.
- Started
-
Oct 2015
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment ?wait and watch? or have received two cycles of chemotherapy or localized radiation therapy before going on this study) non-Hodgkin?s lymphoma or CLL * Patients must have serum 25-hydroxyvitamin D (25\[OH\]D) drawn at time of enrollment; (NOTE: subjects currently taking vitamin D supplements are eligible for screening) * Simultaneous participation in other therapeutic clinical trials will be allowed * Patients must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts Exclusion Criteria: * History of uncontrollable allergic reactions to vitamin D * History of Paget?s disease * Hypercalcemia * Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the investigator?s opinion, may interfere with protocol adherence or a subject?s ability to give informed consent * Inability to cooperate with the requirements of the protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Drug attack on Hard-to-Treat lymphomas
- Patient's own t cells engineered to hunt lymphoma in early trial
- Immunotherapy injection tested against Hard-to-Treat childhood lymphoma
- Two-Drug combo aims to push CLL into deep remission
- Vaccine aims to train immune system against blood cancers
- Can a new BTK inhibitor outsmart resistance in CLL?